vs
Prestige Consumer Healthcare Inc.（PBH）とPITNEY BOWES INC（PBI）の財務データ比較。上の社名をクリックして会社を切り替えられます
PITNEY BOWES INCの直近四半期売上が大きい（$477.6M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.7倍）。Prestige Consumer Healthcare Inc.の純利益率が高く（16.5% vs 5.7%、差は10.8%）。Prestige Consumer Healthcare Inc.の前年同期比売上増加率が高い（-2.4% vs -7.5%）。PITNEY BOWES INCの直近四半期フリーキャッシュフローが多い（$201.4M vs $75.3M）。過去8四半期でPrestige Consumer Healthcare Inc.の売上複合成長率が高い（1.2% vs -4.3%）
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
ピットニーボウズはグローバルなテクノロジー・ロジスティクス企業で、Eコマース配送、郵便処理、フルフィルメント、顧客情報管理ソリューションを提供しています。小売、金融サービス、ヘルスケア、政府部門など、世界中の大中小企業の業務効率化を支援しています。
PBH vs PBI — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $283.4M | $477.6M |
| 純利益 | $46.7M | $27.3M |
| 粗利率 | 55.5% | — |
| 営業利益率 | 29.1% | 8.0% |
| 純利益率 | 16.5% | 5.7% |
| 売上前年比 | -2.4% | -7.5% |
| 純利益前年比 | -23.5% | 173.1% |
| EPS（希薄化後） | $0.97 | $0.18 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $283.4M | $477.6M | ||
| Q3 25 | $274.1M | $459.7M | ||
| Q2 25 | $249.5M | $461.9M | ||
| Q1 25 | $296.5M | $493.4M | ||
| Q4 24 | $290.3M | $516.1M | ||
| Q3 24 | $283.8M | $499.5M | ||
| Q2 24 | $267.1M | $489.7M | ||
| Q1 24 | $277.0M | $521.3M |
| Q4 25 | $46.7M | $27.3M | ||
| Q3 25 | $42.2M | $52.0M | ||
| Q2 25 | $47.5M | $30.0M | ||
| Q1 25 | $50.1M | $35.4M | ||
| Q4 24 | $61.0M | $-37.4M | ||
| Q3 24 | $54.4M | $-138.5M | ||
| Q2 24 | $49.1M | $-24.9M | ||
| Q1 24 | $49.5M | $-2.9M |
| Q4 25 | 55.5% | — | ||
| Q3 25 | 55.3% | — | ||
| Q2 25 | 56.2% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 55.5% | 53.8% | ||
| Q3 24 | 55.5% | 52.4% | ||
| Q2 24 | 54.7% | 51.1% | ||
| Q1 24 | 54.8% | 52.3% |
| Q4 25 | 29.1% | 8.0% | ||
| Q3 25 | 29.1% | 14.8% | ||
| Q2 25 | 28.8% | 8.5% | ||
| Q1 25 | 29.8% | 9.5% | ||
| Q4 24 | 31.7% | -9.3% | ||
| Q3 24 | 29.7% | -8.8% | ||
| Q2 24 | 27.0% | -1.6% | ||
| Q1 24 | 29.7% | 9.1% |
| Q4 25 | 16.5% | 5.7% | ||
| Q3 25 | 15.4% | 11.3% | ||
| Q2 25 | 19.0% | 6.5% | ||
| Q1 25 | 16.9% | 7.2% | ||
| Q4 24 | 21.0% | -7.2% | ||
| Q3 24 | 19.2% | -27.7% | ||
| Q2 24 | 18.4% | -5.1% | ||
| Q1 24 | 17.9% | -0.6% |
| Q4 25 | $0.97 | $0.18 | ||
| Q3 25 | $0.86 | $0.30 | ||
| Q2 25 | $0.95 | $0.17 | ||
| Q1 25 | $1.00 | $0.19 | ||
| Q4 24 | $1.22 | $-0.21 | ||
| Q3 24 | $1.09 | $-0.75 | ||
| Q2 24 | $0.98 | $-0.14 | ||
| Q1 24 | $0.98 | $-0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $62.4M | $297.1M |
| 総負債低いほど良い | $1.0B | $2.0B |
| 株主資本純資産 | $1.8B | $-802.4M |
| 総資産 | $3.5B | $3.2B |
| 負債/資本比率低いほどレバレッジが低い | 0.56× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $62.4M | $297.1M | ||
| Q3 25 | $119.1M | $336.0M | ||
| Q2 25 | $139.5M | $300.8M | ||
| Q1 25 | $97.9M | $340.0M | ||
| Q4 24 | $50.9M | $486.1M | ||
| Q3 24 | $51.5M | $575.5M | ||
| Q2 24 | $34.3M | $612.0M | ||
| Q1 24 | $46.5M | $538.0M |
| Q4 25 | $1.0B | $2.0B | ||
| Q3 25 | $993.1M | $2.1B | ||
| Q2 25 | $992.7M | $1.9B | ||
| Q1 25 | $992.4M | $1.9B | ||
| Q4 24 | $992.0M | $1.9B | ||
| Q3 24 | $1.1B | $2.1B | ||
| Q2 24 | $1.1B | $2.1B | ||
| Q1 24 | $1.1B | $2.1B |
| Q4 25 | $1.8B | $-802.4M | ||
| Q3 25 | $1.8B | $-661.5M | ||
| Q2 25 | $1.9B | $-536.8M | ||
| Q1 25 | $1.8B | $-535.9M | ||
| Q4 24 | $1.8B | $-578.4M | ||
| Q3 24 | $1.7B | $-518.9M | ||
| Q2 24 | $1.7B | $-427.9M | ||
| Q1 24 | $1.7B | $-392.4M |
| Q4 25 | $3.5B | $3.2B | ||
| Q3 25 | $3.4B | $3.3B | ||
| Q2 25 | $3.4B | $3.2B | ||
| Q1 25 | $3.4B | $3.3B | ||
| Q4 24 | $3.3B | $3.4B | ||
| Q3 24 | $3.3B | $3.6B | ||
| Q2 24 | $3.3B | $4.1B | ||
| Q1 24 | $3.3B | $4.1B |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.68× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $78.3M | $221.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $75.3M | $201.4M |
| FCFマージンFCF / 売上 | 26.6% | 42.2% |
| 設備投資強度設備投資 / 売上 | 1.1% | 4.2% |
| キャッシュ転換率営業CF / 純利益 | 1.68× | 8.11× |
| 直近12ヶ月FCF直近4四半期 | $267.2M | $317.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $78.3M | $221.7M | ||
| Q3 25 | $57.5M | $66.8M | ||
| Q2 25 | $79.0M | $111.4M | ||
| Q1 25 | $61.8M | $-16.7M | ||
| Q4 24 | $65.1M | $134.5M | ||
| Q3 24 | $69.8M | $14.7M | ||
| Q2 24 | $54.8M | $92.6M | ||
| Q1 24 | $66.9M | $-12.6M |
| Q4 25 | $75.3M | $201.4M | ||
| Q3 25 | $55.4M | $51.1M | ||
| Q2 25 | $78.2M | $98.0M | ||
| Q1 25 | $58.4M | $-33.6M | ||
| Q4 24 | $63.5M | $112.3M | ||
| Q3 24 | $67.8M | $-4.7M | ||
| Q2 24 | $53.6M | $76.1M | ||
| Q1 24 | $63.8M | $-26.9M |
| Q4 25 | 26.6% | 42.2% | ||
| Q3 25 | 20.2% | 11.1% | ||
| Q2 25 | 31.3% | 21.2% | ||
| Q1 25 | 19.7% | -6.8% | ||
| Q4 24 | 21.9% | 21.8% | ||
| Q3 24 | 23.9% | -0.9% | ||
| Q2 24 | 20.1% | 15.5% | ||
| Q1 24 | 23.0% | -5.2% |
| Q4 25 | 1.1% | 4.2% | ||
| Q3 25 | 0.8% | 3.4% | ||
| Q2 25 | 0.3% | 2.9% | ||
| Q1 25 | 1.2% | 3.4% | ||
| Q4 24 | 0.5% | 4.3% | ||
| Q3 24 | 0.7% | 3.9% | ||
| Q2 24 | 0.4% | 3.4% | ||
| Q1 24 | 1.1% | 2.7% |
| Q4 25 | 1.68× | 8.11× | ||
| Q3 25 | 1.36× | 1.29× | ||
| Q2 25 | 1.66× | 3.72× | ||
| Q1 25 | 1.23× | -0.47× | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.12× | — | ||
| Q1 24 | 1.35× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
PBI
| Sales And Services | $218.4M | 46% |
| Presort Services | $159.7M | 33% |
| Financing And Other | $79.0M | 17% |
| Other | $20.5M | 4% |
